BridgeMD
HALT : Influence of Human Albumin supplementation on kidney dysfunction after Liver Transplantation
EU CTIS ID: 2024-514804-14-00
What this study is testing
To verify whether albumin administration to achieve serum concentration above 30g/L (treated group) and its maintenance within plasmatic physiologic range (>30 g/L) for five days diminishes rate of AKI at Day 7 after liver transplantation as compared to restrained albumin administration (when serum concentration is at 20 g/L or below (control)).
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- IC1 - Male and female patients equal or above 18 yrs old.
- IC2 - Recipients of primary liver allografts from a deceased donor (including after cardiac death) and as a single organ (liver only).
- IC3 - Capability of understanding the purpose and risks of the study.
- IC4 - Written informed consent
You likely can't join if
- NIC1 - Fulminant hepatitis
- NIC2 - Kidney injury at baseline (eGFR < 50 ml/min in MDRD) including hepatorenal syndrome
- NIC3 - Use of an induction agent Basiliximab at liver transplantation
- NIC4 - Protected person (adults legally protected, under judicial protection, guardianship, or supervision), person deprived of their liberty
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.